Randomized trial · people

MK-677 plus alendronate: 4.2% femoral neck BMD gain vs 2.5% alone

Checked against the paper Randomized trialPublished by PepVault

The takeaway

In older women with osteoporosis, MK-677 raised IGF-1 and bone turnover markers, but adding it to alendronate improved bone density only at the femoral neck, which the authors weighed against growth hormone side effects.

Kind
Randomized trial
Studied in
People
Number studied
292
Published
2001
Journal
J Clin Endocrinol Metab

What they tested

The team tested whether adding MK-677 to alendronate, a bone loss drug, would keep bone building higher and raise bone density more than alendronate alone in women with postmenopausal osteoporosis.

How the study was done

A multicenter, randomized, double-blind, placebo-controlled trial in 292 women aged 64 to 85 with low femoral neck bone density. For 12 months they took daily MK-677 25 mg plus alendronate 10 mg, alendronate alone, MK-677 alone, or placebo (dummy pills). The MK-677-alone and placebo groups then switched to the combination for months 12 to 18, and everyone took 500 mg/day calcium.

A woman in glasses at a kitchen table with a laptop, a mug and her phone

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

What they found

At 12 months, IGF-1 (insulin-like growth factor I) rose 39% and 45% from baseline in the two groups taking MK-677, compared with placebo. MK-677 alone raised osteocalcin, a blood marker of bone formation, by 22% and urinary NTx, a marker of bone breakdown, by 41% versus placebo. Compared with alendronate alone, the combination softened the drop in osteocalcin (-40% vs. -54%) and in NTx (-52% vs. -61%). Bone mineral density at the femoral neck rose 4.2% with the combination versus 2.5% with alendronate, but the combination did no better at the lumbar spine, total hip or total body.

What it doesn’t show

The extra bone density gain showed up at only one of four sites measured, and people taking MK-677 had side effects linked to higher growth hormone, though few quit because of them. The trial included only older women with postmenopausal osteoporosis, and bone marker results were for 12 months.

The paper

Murphy et al. Effect of alendronate and MK-677 (a growth hormone secretagogue), individually and in combination, on markers of bone turnover and bone mineral density in postmenopausal osteoporotic women. J Clin Endocrinol Metab. 2001.

The compound

More studies on MK-677

Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.

Track it in the app

PepVault for iPhone

Taking MK-677? Keep your own record

Log each dose, your weight and how you feel, in one place.

Download on the App Store

7 days free on the yearly plan for new subscribers.

Explore the live demo